2015
Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US
Jarrin I, Moreno S, Ingle S, May M, Sterling T, Justice A, Bickel M, Crane H, Mugavero M, De Wolf F, Jung N, Cescon A, Garcia I, Elzi L, Arminio A, Krause M, Smith C, Guest J, Hessamfar M, Gill J, Sterne J, del Amo J. Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US. Antiviral Therapy 2015, 20: 21-28. PMID: 24675571, DOI: 10.3851/imp2768.Peer-Reviewed Original ResearchConceptsNon-AIDS mortalityInjection drug useAll-causeAntiretroviral therapyAIDS-mortality rateNon-AIDS-related mortalityCause-specific mortalityCD4(+) T-cell countsNon-AIDS infectionsRates of all-causeNon-AIDS malignanciesART Cohort CollaborationT-cell countsHIV-infected adultsHIV-positive patientsHIV-1 RNAAll-cause mortalityCox proportional hazards modelsCohort of individualsHIV-positive menProportional hazards modelART-CCSex differencesCART initiationCause-specific
2013
An internationally generalizable risk index for mortality after one year of antiretroviral therapy
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS 2013, 27: 563-572. PMID: 23095314, PMCID: PMC4283204, DOI: 10.1097/qad.0b013e32835b8c7f.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlanine TransaminaseAnti-HIV AgentsAspartate AminotransferasesBiomarkersCD4 Lymphocyte CountCohort StudiesEuropeFemaleHemoglobinsHepatitis CHIV InfectionsHumansMaleMiddle AgedMultiple Organ FailurePlatelet CountPredictive Value of TestsRisk AssessmentRNA, ViralUnited StatesConceptsHIV-1 RNAVeterans Aging Cohort StudyMultiorgan system injuryCD4 cell countAntiretroviral therapyVACS IndexSystem injuryCell countDetectable HIV-1 RNAART Cohort CollaborationOutcome of deathAging Cohort StudyHepatitis C statusMortality risk indexGood discriminationART initiationCohort CollaborationHCV coinfectionCohort studyHIV deathsHIV markersHIV infectionValidation cohortAlanine transaminaseExcess mortality
2011
The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J, Collaboration F. The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine 2011, 13: 89-97. PMID: 21819529, PMCID: PMC4539012, DOI: 10.1111/j.1468-1293.2011.00940.x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDisease ProgressionDrug Therapy, CombinationDrug UsersFemaleHIV InfectionsHumansMaleMiddle AgedOdds RatioProportional Hazards ModelsRisk FactorsRNA, ViralSubstance Abuse, IntravenousViral LoadYoung AdultConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countDisease progressionCell countCART initiationAntiretroviral therapyHigher baseline HIV viral loadLower baseline CD4 cell countBaseline HIV viral loadSpecific causesART Cohort CollaborationLiver-related deathHIV viral loadHIV-positive individualsRisk of deathCause of deathDrug use historyCohort CollaborationCohort studyCumulative incidenceHazard ratioHIV diseaseClinical AIDSPrior diagnosis
2009
Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression
Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA. Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 52: 357-363. PMID: 19668084, PMCID: PMC3032437, DOI: 10.1097/qai.0b013e3181b62933.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyCD4 cell countBaseline CD4 cell countBaseline CD4 countCD4 countImmunologic responseVirologic suppressionCell countAntiretroviral therapyAbsolute CD4Absolute CD4 cell countCD4 cell count strataAdequate immunologic responseART Cohort CollaborationClear therapeutic goalsTreatment-naive individualsCell count strataCART initiationCohort CollaborationCD4 changeHazard ratioViral loadEligible participantsSubsequent prognosisClinical significancePrognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements
Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte A, Force L, Gill J, Harris R, Hogg R, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne J, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009, 23: 2199-2208. PMID: 19779320, PMCID: PMC3122149, DOI: 10.1097/qad.0b013e3283305a00.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyCD4 cell countHIV-1-infected patientsHIV-1 RNAViral loadCART initiationCell countStart of cARTHIV-1 RNA measurementsART Cohort CollaborationMedian CD4 cellPredictors of AIDSRates of AIDSImportant prognostic factorPrognosis of patientsCohort CollaborationSubsequent AIDSAntiretroviral therapyHIV cohortCD4 cellsPrognostic factorsPrognostic importanceCopies/PatientsAIDSMortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal Of Epidemiology 2009, 38: 1624-1633. PMID: 19820106, PMCID: PMC3119390, DOI: 10.1093/ije/dyp306.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCause of DeathCD4 Lymphocyte CountCohort StudiesFemaleHIVHIV InfectionsHomosexuality, MaleHumansMaleMortalityPrevalenceProspective StudiesRisk FactorsSubstance Abuse, IntravenousViral LoadVirus ReplicationConceptsCD4 cell countAntiretroviral therapyCells/microLGeneral populationCell countEligible patientsExcess mortalityCopies/Start of ARTViral replicationART Cohort CollaborationCorresponding general populationMortality of HIVPotent antiretroviral therapyCombination antiretroviral therapyPercentage of patientsProspective cohort studyInjection drug useViral load measurementsNumber of deathsCohort CollaborationCohort studyMedian ageViral loadClinical stage
2002
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne J, Collaboration T. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet 2002, 360: 119-129. PMID: 12126821, DOI: 10.1016/s0140-6736(02)09411-4.Peer-Reviewed Original ResearchConceptsCells/microLCD4 cell countBaseline CD4 cell countActive antiretroviral therapyProbability of progressionCell countAntiretroviral therapyCohort studyBaseline HIV-1 viral loadCD4 cells/microLCD4 cells/microL.HIV-1 viral loadHIV-1-infected patientsART Cohort CollaborationTreatment-naive patientsCells/microL.Dominant prognostic factorFuture treatment guidelinesInjection drug useHigh-risk stratumLow-risk stratumSingle cohort studyCohort CollaborationNew AIDSAdult patients